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A B S T R A C T
Inflammatory bowel disease (IBD) is a debilitating chronic inflammatory disease of the gastrointestinal (GI)
tract. It affects more than 3.5 million people in the western world and places a huge financial burden on
healthcare systems. IBD is highly heterogeneous; disease severity and outcomes in IBD are highly variable, and
patients may experience episodes of relapse and remission. However, treatment often follows a step-up model
whereby the patients start with anti-inflammatory agents (corticosteroids or immunosuppressants) and step-up
to monoclonal anti-tumour necrosis factor-α (TNFα) antibodies and then other biologics if the initial drugs
cannot control disease. Unfortunately, many patients do not respond to the costly biologics, and thus often still
require gut-resective surgery, which decreases quality of life. In order to decrease rates of surgery and ineffective
treatments, it is important to identify markers that accurately predict disease progression and treatment re-
sponses, to inform decisions about the best choice of therapeutics. Here we examine molecular approaches to
patient stratification that aim to increase the effectiveness of treatments and potentially reduce healthcare costs.
In the future, it may become possible to stratify patients based on their suitability for specific molecular-targeted
therapeutic agents, and eventually use molecular stratification for personalised medicine in IBD.
1. Introduction
Inflammatory bowel disease (IBD) is a term describing disease
characterised by chronic gastrointestinal inflammation in a protracted
relapsing and remitting course. IBD affects over 3.5 million people in
the western world with incidence substantially increasing in recent
decades [1]. It equally affects males and females and has a peak age of
onset in the teenage years and early adulthood [2].
Crohn’s disease (CD) and ulcerative colitis (UC) are the two most
common forms of IBD and differ in disease mechanism and location
[3,4]. UC is a mucosal disease with continuous ulceration always af-
fecting the mucosa of the rectum that can spread proximally into the
colon [4]. A major complication of UC is the potentially life-threatening
toxic megacolon, an expansion of the colon often necessitating co-
lectomy [5]. In contrast to UC, CD can affect the entire GI tract from
mouth to anus and the inflammation often penetrates the mucosa in-
stead of solely superficially affecting the inner lining [4]. Ulcerations in
CD are not continuous and occur in “skip lesions”, where healthy areas
separate inflamed tissue. CD patients can experience a spectrum of
complications, including strictures (narrowing of the intestinal lumen)
and fistulae (abnormal connections between intestines and other or-
gans) [6]. Unlike in CD, surgery is curative in UC [7] but it does carry
significant inherent surgical risks including small bowel obstructions,
sepsis, neural injury and haemorrhage [8]. Furthermore, quality of life
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does not return to normal after colectomy in UC [9].
IBD patients can experience a range of symptoms during active
disease, including bloody diarrhoea, abdominal pain, weight loss,
perianal discomfort, growth impairments, and faecal urgency to name
but a few [6,10]. These symptoms have a significant impact on ev-
eryday life. As well as in increased risk of colonic cancer in patients
with colonic disease [11], patients with IBD may also develop extra-
intestinal manifestations (EIMs). Up to 40% of patients experience pa-
thological inflammation in non-GI organs [12], however the risk for
and location of these EIMs is not predictable.
Due to the requirement of continuous monitoring and treatment to
manage disease and minimise its impact on the quality of life, IBD
creates a huge financial burden on healthcare systems, and has sub-
stantial indirect economic impacts [13,14]. It has been estimated that
the costs of IBD in the US in 2014 was between $14.6–31.6 billion. The
financial burden of IBD for the UK National Health Service in 2010 was
around £3000 per patient, with overall costs of approximately £1 bil-
lion [15]. Although IBD management is expensive, only around 60–70%
of patients are satisfactorily managed [16,17]. Here we discuss the
limitations of current therapeutic models, the need for treatment ad-
vances in IBD and suggest the potential use of molecular stratification
to improve IBD therapy. Molecular stratification distinguishes patients
on a molecular level, e.g. by using genetic, transcriptomic, micro-
biological or proteomic information. This approach has the potential to
successfully improve targeted therapy both IBD and in other in-
flammatory diseases such as rheumatoid arthritis.
2. The aetiology of IBD
IBD has a complex aetiology involving a variety of overlapping
factors, including immune dysregulation, genetics and environmental
factors [18]. The precise causes of IBD are unknown but, due to loss of
epithelial barrier integrity in the intestine, microbes are translocated
into the intestinal wall and their detection and attempted clearance by
the immune system causes inflammation [19,20]. The homeostatic re-
lationship between the intestinal immune system and commensal gut
microbiota is disturbed, resulting in an abnormal intestinal immune
response and subsequent pathological chronic inflammation. Im-
munological and genetic studies have elucidated many critical disease
mechanisms.
2.1. Immunopathology of IBD
CD4+T cells are key to the adaptive immune response and have
been identified as important drivers of inflammation in IBD. Upon re-
cognition of their cognate antigen presented by antigen presenting cells
(APCs), naïve CD4+T cells can differentiate into several distinct T
helper (Th) cell types. Each expresses a unique set of cytokines and
specific transcription factors (Fig. 1). Th1 cells have been described as
important in the pathogenesis of CD, while Th2 cells are reported to be
more involved in mediating inflammation in UC. Recent genome-wide
associated studies (GWAS) have indicated that the Th17 pathway is of
great importance in both CD and UC inflammation. Indeed, it is now
widely accepted that a shift in the Th17/Treg balance towards pro-in-
flammatory Th17 cells and away from immunoregulatory Tregs is an
essential component of IBD immunopathology [21,22].
To enable T cells to efficiently localise to the intestine they express
specific homing receptors [23]. Intestinal endothelial cells express
Mucosal Addressin Cell Adhesion Molecule-1, which adheres to the
integrin α4β7 on Th and other immune cells and helps their entry into
the intestine [24].. However, once the intestine becomes inflamed a
large number of chemotactic receptors and cell adhesion molecules are
likely to be capable of mediating T cell homing.
After localisation to the intestine T cell responses are driven by
direct contact with antigen-presenting cells (APCs) but are shaped by
the cytokine environment created by APCs and other immune cells. For
instance, after initial activation and differentiation to Th1 (in response
to IL-12) or Th2 cells (in response to IL-4), both Th1 and Th2 cells
secrete tumour necrosis factor-α (TNF), a pro-inflammatory cytokine
known to drive inflammation in UC and CD. In addition, upon differ-
entiation, Th17 cells express the IL-23 receptor, enabling them to re-
spond to the IL-23 produced in inflamed tissues, which enhances their
survival [21,22]. IL-23 also inhibits Treg inhibitor, reducing their ex-
pression of the regulatory cytokine IL-10. Thus, inhibition of Tregs by
IL-23 also promotes the Th17 response [21,22].
2.2. Genetic predisposition to IBD
From loss of epithelial barrier integrity to dysregulation of intestinal
immunity, there are a large number of biological processes that con-
tribute to the development and progression of IBD. GWAS have iden-
tified over 200 genetic susceptibility loci associated with IBD [25,26],
but genetic predisposition is usually not enough for IBD onset. An ex-
ception is monogenic IBD, prevalently found in paediatric patients,
where a single genetic factor causes disease [27]. The penetration of
susceptibility loci is estimated to be 30% in CD and 20% in UC patients.
Many of these loci are located in immune genes, including those in-
volved in innate and adaptive immune responses, and have been as-
sociated with other autoimmune diseases. Although there are specific
gene variants associated with either CD or UC, the majority are shared
by both forms of IBD [25].
Although GWAS have identified many susceptibility gene variants,
our understanding of how each of the identified polymorphisms con-
tribute to IBD development is still somewhat limited. Moreover, most
IBD patients are likely to have multiple low-penetrance IBD suscept-
ibility alleles, which alone would not be sufficient to induce IBD, con-
sistent with the multifactorial aetiology of IBD [28].
3. Current treatment: step-up therapy
Despite the heterogeneity of IBD, most patients are treated using the
same empirical step-up therapy approach in which increasingly pow-
erful and generally more expensive drugs are prescribed in a step-wise
manner (Fig. 2). Since there is no pharmacological cure for IBD, the
step-up model focuses on controlling and alleviating intestinal in-
flammation by maintaining clinical remission of patients and inducing
healing of ulcerated mucosa.
3.1. Corticosteroids, aminosalicylates and immunosuppressants
The conventional first-line treatment for many IBD patients is a
corticosteroid monotherapy [29,30]. In UC aminosalicylates (5-ASA)
drugs are administered as a common alternative to corticosteroids and
are often sufficient to control disease, however, 5-ASA treatment is
ineffective in CD [31]. Due to their severe adverse effects [32], corti-
costeroids are not suitable for long-term administration. Additionally,
there is a wide range of contraindications that do not allow corticos-
teroid treatment [33]. The corticosteroid dosage is gradually lowered
after clinical remission is induced, but if the patients relapse after
corticosteroid withdrawal, immunosuppressants (e.g. mercaptopurine,
azathioprine or methotrexate) may be are added; these can be ad-
ministered long-term and used to maintain remission [29,30]. When
patients are intolerant or only partially responsive to these first-line
therapeutics, they may receive biologic therapy.
3.2. Biologics – targeted IBD therapeutics
Biologics block the action of specific molecular targets involved in
IBD development and/or progression. The most commonly prescribed
biologics are the anti-TNF agents, which bind the cytokine TNFα and
inhibit its pro-inflammatory activity. Two commonly used anti-TNF
drugs licensed for use in the EU are infliximab (IFX) and adalimumab.
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They have been reported to achieve up to 47% or 33% long-term re-
mission in patients with CD (adalimumab) [34] or UC (infliximab) [35],
respectively.
If anti-TNF therapy is ineffective, not tolerated or contraindicated,
non-TNF targeting biologics or small molecules may be issued. Two
such biologics licensed for use in the EU are vedolizumab (UC/CD)
[36,37] and ustekinumab (CD only at present) [38]. vedolizumab binds
α4β7 integrin to prevent homing of immune cells from the blood into
the intestine. ustekinumab targets IL-12 and IL-23 by binding their
shared p40 subunit (encoded by the IL12B gene) [38], which prevents
these cytokines from binding to their respective receptors, thereby
preventing the differentiation of Th1 cells and the amplification of
Th17 cells. ustekinumab is currently licensed for treatment of CD, but
may also have efficacy in patients with UC [39]. Very recently the
Janus kinase (JAK) inhibitor tofacitinib, which inhibits enzymes in-
volved in cytokine signalling, has been introduced into IBD for UC
treatment only, as an alternative if biologic treatment failed [40,41].
The introduction of biologics has been an important advance in the
treatment of IBD. Unlike corticosteroids and immunosuppressants,
biologics target receptors or soluble molecules to suppress specific pro-
inflammatory pathways, reducing the risks of side effects. Compared to
the other IBD treatments, biologics can also induce high rates of mu-
cosal healing, defined as the absence of ulcerations when assessed en-
doscopically. With front-line anti-TNF biologics, this is reported to be
achieved in 44% and 46% of CD and UC patients, respectively [42,43].
High specificity gives biologics potent therapeutic benefits, however, in
a heterogenous disease like IBD, high specificity increases the chance
that some recipients may not respond. This might be due to the in-
dividual’s disease not being reliant on the specific protein that is being
targeted.
Although the step-up therapy model described above can be effec-
tive and can allow satisfactory disease management of UC, with surgery
rates dropping to 4–16% in recent years, 30–40% of CD patients still
eventually require bowel surgery [16,44,45]. Increasingly, therefore, a
top-down therapy model is used. Here, biologics are used to manage
disease early in the treatment process for patients with severe IBD.
Should remission be achieved, other treatments may be used to main-
tain this state. A top down strategy is increasingly employed in those
presenting with severe disease at the outset and penetrating compli-
cation in CD. Such a strategy is often limited by cost and local health-
care policies.
4. Molecular stratification: personalised medicine for IBD
treatment?
The heterogeneity and complex pathogenesis of IBD mean that a
‘one-size-fits-all’ standardised treatment, be it step-up or top-down, may
not be effective. If possible, adapting the therapy to the individual
Fig. 1. The generation of T helper cell subsets in the in-
testine and their cytokine production profiles. Th1, Th2
and Th17 cells are involved in IBD immunopathogenesis
through their production of the cytokines indicated and are
polarized by activated APCs. Th17 cells can inhibit FoxP3+
Treg cells through IL-23, while FoxP3+ Treg cells can sup-
press Th17 cells using IL-10. The Th17/Treg balance is com-
promised in IBD patients.
Fig. 2. Current approaches to IBD treat-
ment. Patients following step-up therapy are
given frontline therapies, such as corticoster-
oids and aminosalicylates, followed by im-
munosuppressants, anti-TNF and non-TNF tar-
geting biologics and JAK inhibitor tofacitinib
(UC only) in a step-wise manner. Proceeding to
the next therapy step depends on treatment
responses, side effects and disease severity. An
alternative treatment model, top-down therapy
may be useful for patients with severe IBD. In
this strategy, more specific biologics are ad-
ministered sooner after diagnosis.
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characteristics of the patient’s condition would be a better treatment
approach. This ‘personalised medicine’ approach aims to customise
treatment according to the needs of each individual patient, based on a
detailed characterisation of their disease mechanism, genetics and en-
vironmental factors. A key step towards this goal involves using mo-
lecular information to stratify patients into discrete groups.
Here, we describe two types of molecular stratification that could be
integrated into the existing step-up and top-down approaches for IBD
treatment. First, stratification may be used to predict disease progres-
sion (such as disease severity and risk of relapse) and treatment re-
sponses. In individuals predicted to have a milder form of disease,
milder therapeutics may well be sufficient, whereas patients with a
prediction for severe disease may require treatments with biologics
straight away. Additionally, type of therapy or drug dosage can be
adjusted sooner if a shorter clinical remission period is suspected.
Second, identifying patients prior to treatment who are likely to re-
spond to specific drugs would improve clinical outcomes, avoid un-
necessary side effects, and reduce healthcare costs. With anti-TNFs
costing between £3000 and £12,000 per patient annually, giving them
to patients that will not respond is an expensive waste of healthcare
resources.
Initially, molecular stratification could help improve the effective-
ness of current treatment models by introducing elements of persona-
lised medicine, but the ultimate aim is to move away from established
treatment models and develop fully personalised medicine. Therefore,
in the final part of this review, we discuss the potential of using mo-
lecular stratification as a basis for personalised medicine for IBD in the
future.
5. Molecular stratification to predict disease progression
Predicting disease severity and outcome in IBD could inform clinical
decision-making. Disease evaluation in the clinics is currently mainly
based on imaging techniques and patient well-being. However, it would
be very useful to introduce biomarkers that can identify inflammation
before patients’ well-being is substantially affected or before they have
mucosal damage detectable by imaging. This could allow prophylactic
treatments to be started, and guide the decision to proceed to biologic
therapy, while also helping to identify IBD patients likely to develop
complications. Additionally, the dynamic nature of UC and CD makes it
important to develop tools that can predict the risk of relapse. This is
essential to differentiate patients that have a mild form of IBD from
those that are in remission and may require adjustments in treatment to
prevent relapse. Several methods are outlined here that have been
employed to try to predict disease severity and outcome.
5.1. Serological markers
C-reactive protein (CRP) is currently the main serological marker in
clinical use for IBD diagnosis and monitoring [46]. CRP is has been
found to have poor sensitivity and specificity, which limits its utility. It
is raised in any inflammatory illness, including infections such as flu,
but is not infrequently normal in those with active IBD [47,48] Due too
poor sensitivity and specificity, other serological markers are currently
not in clinical use. However, peripheral biomarkers either in blood or
stool samples are necessary to enable stratification, so researchers have
been exploring the potential of a selection of such biomarkers.
A commonly examined serological marker in research is
anti–Saccharomyces cerevisiae antibody (ASCA), which is often elevated
in IBD patients, especially those with CD [49]. ASCA binds to mannans,
a polymer of mannose in yeast cell walls. Increased ASCA in severe CD
is assumed to reflect loss of immune tolerance to yeast in the gut [50].
Ferrante and colleagues studied 1538 IBD patients (75% CD; 22% UC;
3% indeterminate colitis) and found a correlation of high ASCA anti-
body titres with high risk of disease complications, such as fistulaes and
surgery [51]. Another serological marker with potential to predict
disease outcomes in UC is perinuclear anti-neutrophil cytoplasmic an-
tibody (pANCA), which recognises proteins in the nucleus of neu-
trophils. An increase in pANCA suggests strong neutrophil-driven in-
nate inflammation, which has previously been monitored in UC patients
by measuring proteins associated with neutrophil extracellular traps
[52]. High pANCA levels have been associated with chronic pouchitis
(p= 0.03), inflammation of the ileal pouch in UC patients that have
undergone colectomy [53]. In UC and CD, elevated pANCA titres have
also been identified as an indicator for EIMs including uveitis
(p= 0.005) and erythema nodosum (p= 0.001) [54]. An association
between biomarkers and EIMs could allow additional sites of in-
flammation to be identified and treated more rapidly. The same study
[54] also linked HLA-B27, an allele of the major histocompatibility
complex I, to EIMs: 33.3% of HLA-B27-positive IBD patients in the
cohort had developed ankylosing spondylitis, an inflammatory condi-
tion mainly affecting the spine and joints.
Although pANCA or ASCA have high specificity their sensitivity is
low, and the tests are therefore currently not in clinical use [55]. With
recent advances in understanding the disease mechanisms of IBD and
the role of immune cells, other approaches could involve the analysis of
cells in peripheral blood. For example, Joosse and colleagues [56]
analysed the transcriptome of CD38+CD4+T cells, which are effector
T cells found at mucosal sites [56,57]. These activated T cells travel in
the bloodstream before entering tissues so can be isolated from blood
samples. They can express TIGIT, a receptor that can inhibit T cell ac-
tivation. Based on the transcriptional profile of CD38+CD4+T cells
isolated from paediatric IBD patient blood, low expression of TIGIT by
these cells correlates with shorter periods of clinical remission. Patients
with< 25% TIGIT+CD38+CD4+T cells in the peripheral blood had
a significantly shorter remission period than those with>25%
TIGIT+ cells (p < 0.05). To our knowledge, this is the first report
using peripheral blood samples to monitor tissue-localised T cells and
they suggest that TIGIT down-regulation may help promote T cell-
driven mucosal inflammation. In order to appreciate the full predictive
value of these findings, it will be important to establish the stability of
these differences in TIGIT expression and understand how
CD38+CD4+T cells traffic into and out of the affected mucosal sites.
This pilot study may indicate that immunopathology may be assessed in
future to develop disease-monitoring markers.
5.2. Faecal calprotectin
Analysis of faecal calprotectin levels has revolutionised the IBD field
and is used in clinical practice as first line of IBD diagnosis in addition
to other diagnostic tests. A faecal calprotectin test can determine
whether a patient requires further gastroenterological examinations. It
is an indicator of ongoing neutrophil-driven inflammation, because it is
highly abundant in the cytoplasm of neutrophils. When neutrophils
rupture during intestinal inflammation, calprotectin is released into the
tissue, from where it is secreted into the faeces. It is therefore a useful
marker of intestinal inflammation. A pioneering study by Røseth and
colleagues found, using 62 UC patients, a strong positive correlation
between increased faecal calprotectin and the level of intestinal in-
flammation as determined by endoscopic and histologic analysis
(p < 0.0001) [58]. However, this study did not identify calprotectin as
a predictive marker, but rather as a marker that allows the level of
active neutrophilic inflammation to be quantified at the moment of
sampling.
In order to investigate its use as a predictive biomarker of in-
flammation, calprotectin has been studied in the context of clinical
relapse. Tibble and colleagues monitored a total of 80 IBD patients with
either CD or UC for one year and observed that faecal calprotectin le-
vels of> 50mg/l had a sensitivity of 90% and specificity of 83% to
predict relapse [59]. These findings were supported by a study that
used 130mg/kg of faecal calprotectin as the cut-off; the frequency of
relapse was substantially higher in the calprotectin-positive group
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(˜59%) than the calprotectin-low/negative cohort (21%) [60]. This
study also revealed that CD patients with colonic inflammation showed
a significant correlation (p=0.02) between relapse and calprotectin
levels, whereas CD patients without colonic inflammation did not. In a
separate study, Gisbert and colleagues studied the relationship between
calprotectin and relapse in a cohort of 163 IBD patients [61]. The
sensitivity (69%) and specificity (69%) to predict relapse were lower
than the previous studies, potentially based on the use of a higher cut-
off concentration (150 μg/g faecal calprotectin) and conjoined analysis
of UC and CD. Naismith et al. have looked at the correlation between
faecal calprotectin levels and relapse behaviour in CD patients over a 12
months period (n=92). With 240 μg/ml as cut-off point, faecal cal-
protectin could predict relapse with a sensitivity of 80% and specificity
of 74.4% [62]. A meta-analysis by Mao et al. investigated the associa-
tion between relapse and faecal calprotectin levels in a cohort of 672
IBD patients (nUC= 318, nCD= 354) derived from 6 different studies
[63]. Cut-off varied between 120 μg/g and 340 μg/g. The marker could
predict relapse in IBD remission patients with 78% sensitivity and 73%
specificity. Again, faecal calprotectin was reported to have a higher
potential in predicting relapse in CD affecting the colon than in disease
restricted to the small bowel, reinforcing the need of an additional
marker for non-colonic disease.
Faecal calprotectin’s main clinical use is to distinguish IBD patients
from other individuals with bowel-related conditions and to assess the
effectiveness of therapies as a low calprotectin level is a surrogate
maker for mucosal healing [64], but has also been established as
marker for determining the risk of relapse.
5.3. Genomics and transcriptomics
The genome offers a huge range of potential biomarkers, some of
which might prove useful for stratification. Of the>200 IBD suscept-
ibility loci, some have already been associated with certain disease
outcomes. The first gene discovered by genetic analysis to be a driver of
CD was nucleotide-binding oligomerisation domain 2 (NOD2) [65,66].
NOD2 (also known as CARD15) is an intracellular receptor that detects
peptides found on bacterial surfaces and is important for anti-bacterial
immune responses. Additionally, patients with particular variants in
their NOD2 alleles have reduced production of defensin, a molecule
essential for managing the gut microbiota and maintaining intestinal
epithelial barrier integrity [67]. Associated with UC are polymorphisms
in the HLA-DRA gene [68], which codes for the alpha chain of the major
histocompatibility complex II, and potentially alters antigen presenta-
tion. Variation in NOD2/CARD15 has been linked to small bowel ste-
nosis in CD [69]; ˜80% of CD patients that are heterozygous or homo-
zygous for this allele are reported to have developed small bowel
stenosis. Bowel stenosis is a common cause of surgery in IBD [70,71]
and 62% of patients requiring surgery as a consequence of this condi-
tion carried the 1007 fs variant. A larger Dutch cohort study (2804 IBD
patients) [72] identified another NOD2/CARD15 polymorphism
(3020insC) that functioned as a predictor for bowel stenosis
(p= 0.027) and surgery (p= 0.000172). In addition, the rs2241880
polymorphism of ATG16L1 has been associated with strictures
(p=0.005) and perianal inflammation (p=0.035) in CD. If further
studies support the prognostic value of these markers, they could help
identify patients who would benefit from more aggressive im-
munosuppressive treatments to reduce inflammation, avoid bowel ste-
nosis and delay surgery.
The number of interacting gene loci implicated in IBD makes it
challenging to exploit the full potential of genomics to categorise IBD
into discrete immunopathotypes. However, Haritunians and colleagues
used multiple IBD risk loci to categorize UC patients into groups ac-
cording to whether their IBD had resulted in a colectomy [73]. By
analysing 929 refractory UC patients, they were able to use 46 distinct
single nucleotide polymorphisms (SNPs) to define four colectomy risk
groups with risk scores (RS) based on the number of risk alleles in the
patients (ranging between 0–92 i.e. 46 SNPs, 2 alleles). 100% of pa-
tients in “risk group D” with the highest RS (53–60) required co-
lectomy, whereas only 0.9% of colectomy cases were in risk group A,
which had the lowest RS (28–38). This pilot study thus demonstrated a
successful use of genetic information to stratify UC patients with dif-
ferent disease outcomes.
The use of genomics in IBD stratification opens the door to diagnose
patients at a molecular level and delivers unequivocal information that
is independent of when the sample is taken. This may allow risk groups
to be identified, which could have clinical utility, but it fails to ac-
commodate the highly dynamic nature of IBD or the importance of
environmental factors in shaping disease progression. It is therefore
highly unlikely that genomics alone will be able to robustly predict
disease outcome and thus has no yet entered routine clinical practice.
By measuring gene expression, transcriptomics should be more ef-
fective than genomics at identifying different clinical states. For in-
stance. a transcriptomic approach using blood CD8+ T cells from 67
patients with active IBD has been used to successfully identify two
groups according to disease severity [74]. A transcriptional signature
was found that was associated with severe IBD with shorter remission
periods: it was based on increased expression of genes involved in IL-7
function and T cell receptor ligation. Validation in a larger patient co-
hort is required but, if replicated, it may indicate that the evaluation of
individual cell types crucial to IBD pathogenesis could have prognostic
value.
5.4. Analysis of the microbiome
Patients with IBD are known to have a less diverse microbiome than
heathy controls [75,76]. Since a hallmark of IBD pathogenesis is dys-
biosis between the mucosal immune system and gut microbiota, the
microbiome has the potential to harbour species with biomarker ca-
pacity.
A recent study revealed that the analysis of the genetics of the gut
microbiota could be a useful non-invasive way of localising in-
flammation in CD [77]. Identifying the intestinal regions that could
potentially be affected by inflammation is crucial to predicting disease
progression and outcome. Healthy twin pairs were compared to con-
cordant pairs (both with CD) and discordant pairs (one healthy and one
with CD). Patients with ileal or colonic CD were included. Interestingly,
faecal samples from those with ileal CD were reported to have very low
levels of Faecalibacterium prasnitzii and increased levels of Escherichia
coli compared to healthy controls and patients with colonic CD. Ac-
quisition of faecal samples for microbiome analysis is very simple, and
processing is based on well-established techniques. However, the mi-
crobiota quickly adapt to external factors, such as diet [78], so it might
be argued that they may be unreliable markers. However, this adapt-
ability of the microbiota may allow microbial analysis to be exploited as
a method to track dynamic changes in a patient’s disease state.
The potential of microbial analysis to predict relapse risk has re-
cently been studied by Rajca and colleagues [79]. They analysed faecal
samples from 33 CD patients collected at baseline, 2 and/or 6 months
after first IFX treatment and then at 16 months during the follow-up
period. They found lower levels of Bacteroides (p=0.004), Faecali-
bacterium prausnitzii (p= 0.010), and C. coccoides (p= 0.0004) in the
faecal samples of patients that experienced at least one clinical relapse
during the time frame of the study. Interestingly, IFX therapy elevated
the levels of these bacteria and prolonged remission. This study em-
phasises how using microbial analysis to assess the dynamic nature of
IBD could be used to monitor and predict changes in disease over time.
Recent successes in nutritional therapies [80,81], which can reshape
the microbiome composition via changes in diet, have again high-
lighted the importance of the microbiome in IBD pathology. The studies
above are only a small selection of an emerging field with huge po-
tential, not only in therapeutics but also disease monitoring.
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6. Molecular stratification to predict response to biologics
Treatment with biologic agents is currently the closest therapeutics
have come to personalised medicine. After assessing disease severity,
IBD patients with severe disease may receive treatment with biologics.
To decide which biologic is most suitable, it would be desirable to be
able to distinguish likely responders from non-responders before be-
ginning treatment. For both the step-up and top-down models, anti-TNF
is the front-line biologic. Therefore, the ability to predict anti-TNF re-
sponders will improve therapeutic success.
6.1. Predicting anti-TNF responses
6.1.1. Genetic polymorphisms
Single nucleotide polymorphisms (SNPs) are potential biomarkers of
clinical responses. A systematic review by Bek et al. investigated po-
tential genetic markers for treatment response in both CD and UC,
patients. 15 studies were selected with cohort sizes varying between
102–534, and treatment responses were evaluated based on clinical
symptoms and/or antibody response (i.e. CRP levels) at time points
between 2 and 30 weeks. SNPs associated with disease were compared
to frontline anti-TNF treatment responses (IFX or adalimumab).
Variants in toll-like receptor (TLR) 4 (rs55030728), FC fragment of IgG
receptor IIIa (FCGR3A, rs396991), tumour necrosis factor receptor su-
perfamily 1A (TNFRS1A, rs4149570), interferon-gamma (IFNγ,
rs2439561), interleukin-6 (IL-6, rs10499563) and interleukin-1B (IL-
1B, rs4848306) were related to improved treatment response to anti-
TNF in IBD, whereas TLR2 and TLR9 SNPs rs3804099 and rs352139,
respectively, were linked to a weaker response [82]. It is possible that
TNFRSF1A rs4149570 might encode a TNF receptor more susceptible to
anti-TNF treatment. SNPs in FCGR3A and TLRs can potentially be as-
sociated with different IgG antibody and antigen recognition response,
respectively, however it is unclear how this impacts IFX/adalimumab
efficacy. IL-6 and IL-1B are, like TNFα, products of an initial innate pro-
inflammatory immune response and are released downstream of TLR
signalling. Additionally, together with other cytokines, IL-6 is involved
in T cell polarisation. Although similar to polymorphisms in TLR it is
unclear how these variants affect anti-TNF treatment response.
It is known that intestinal T cells in IBD patients display dysfunc-
tional apoptosis [83,84], and that this can be reversed by IFX treatment
[85]. Hlavaty and colleagues reported a relationship between SNPs in
apoptosis-associated genes (Fas ligand and caspase-6) and clinical re-
sponses to IFX treatment in CD patients [86]. In this study, 52.1% of
163 luminal CD patients reached remission 4 weeks after one dose of
IFX, and patients with at least one ‘C allele’ of the Fas ligand gene were
significantly more likely to recover. Interestingly, another study re-
ported that CC genotype in Fas Ligand were four times less responsive
to anti-TNF compared to TT genotype [87]. No correlations were re-
ported between Fas ligand genotypes and any other clinical parameters,
perhaps indicating that the genes influencing response to therapy might
be distinct from those contributing to signs of disease.
An obvious association to anti-TNF response are polymorphisms in
the TNFα gene. A metanalysis investigated polymorphisms in the TNFα
promoter region in IBD and spondyloarthritis [88], an inflammatory
disease affecting the spine and other tissues. In 352 IBD and 211
spondyloarthtitis patients two alleles, 308-G and 857-C, were identified
as predictor for anti-TNF therapy responders. Although the UK National
Health Service may start using genomic medicine in the near future,
genome sequencing for SNP identification in IBD patients is not cur-
rently considered to bring sufficient benefit to justify the associated
costs [89,90].
6.1.2. Immune gene expression
Due to the important role of adaptive immunity in the pathogenesis
of IBD [21], it might be expected that responders and non-responders
would show differences in expression of genes involved in adaptive
immune responses. Toedter and colleagues performed gene expression
analysis on colonic biopsies from 48 UC patients and identified a se-
lection of genes involved with Th1, Th2, and Th17 pathways whose
expression differed between those who did, and those who did not,
respond to IFX [91]. Most of these genes were associated with Th17
responses and they were down-regulated in responders once they re-
ceived IFX, and were lower in IFX-treated responders than IFX-treated
non-responders. These gene expression patterns were validated in ad-
ditional colon biopsies and could be used to distinguished responders
from non-responders with an 81–100% success rate, depending on IFX
dose and treatment [91]. Another study used colon biopsies from two
separate UC cohorts to identify and validate differences in the expres-
sion of 5 genes between IFX non-responders and responders and show
that it could distinguish between these two groups with 89% accuracy
[92]. None of these 5 genes overlapped with those identified by Toedter
and colleagues, but both studies generated transcriptional profiles that
could be useful in predicting and monitoring responses to anti-TNF.
Verstockt et al. studied gene expression in whole peripheral blood
samples of 54 IBD patients with active disease (nCD=23, nUC= 30) at
baseline prior to treatment initiation and followed-up treatment re-
sponse for 24 weeks [93]. Reduced Triggering receptor expressed on
myeloid cells1 (TREM1) expression was linked to anti-TNF responders
in both UC (p= 0.001) and CD (p= 0.007). Analysis of the tran-
scriptome of intestinal biopsies confirmed this target to be also down-
regulated in mucosal tissue of responders and additionally identified
lower levels of oncostatin M (OSM), TNF and TNF receptor 2 (TNFR2).
Since TREM1 could potentially function as a peripheral biomarker for
anti-TNF response it is a very attractive target for future research.
Since TNF is a very important compartment of the pro-inflammatory
immune response with a wide range of down-stream effects, adminis-
tration of TNF blocking agents can induce changes in immune gene
expression. These changes may be a contributing factor to the loss of
response after initial effective treatment, another challenge the IBD
field is facing. A recent study compared gene expression of IBD patients
with (n= 12) and without (n= 12) anti-TNF treatment and healthy
controls [94]. It was found that anti-TNF treatment impaired expression
of lipocalin 2 (LCN2), an antimicrobial peptide, and Treffoil factor 1
(TFF1), an important component of intestinal mucus.
6.1.3. Cytokine expression
Responses to anti-TNFs may be affected by the level of TNFα in the
inflamed tissue at the start of treatment. Atreya and colleagues studied
the baseline level of TNF in patients by administering adalimumab
conjugated to a fluorescent label to allow them to visualise membrane-
bound TNF (mTNFα) in the inflamed intestinal regions using confocal
laser endomicroscopy [95]. This in vivo imaging approach was per-
formed on 25 CD patients who then received further therapeutic doses
of adalimumab. 12 weeks post-treatment the cohort that had had re-
latively high numbers of mTNFα-expressing cells (mean of 30 per
confocal image) had a 92% response rate, while the group with fewer
mTNFα-expressing cells (mean of 11 per confocal image) had a re-
sponse rate of only 15%.
Other studies have examined whether other cytokines and cytokine
receptors could be useful markers of anti-TNF responses [96–98]. West
and colleagues demonstrated that the expression of OSM can be used to
predict response to anti-TNF therapy [96]. Compared to healthy con-
trols, they detected an abundance of OSM and its receptor (OSMR) in
inflamed intestinal tissue from CD and UC patients. High levels of OSM
prior to IFX treatment were strongly associated with a failure to re-
spond to the IFX. Up to 85% of patients with low baseline OSM had
complete mucosal healing, whereas only 10%–15% with high levels
responded to anti-TNF therapy. The authors also observed that high
levels of OSM expression in UC were a predictor of patients that lost
C. Wang, et al. Pharmacological Research 148 (2019) 104442
6
anti-TNF responsiveness ˜30 weeks after initiating treatment.
6.1.4. Proteomics
Improvements in the technology to quantify proteins, proteomics,
have recently been led to proteomic analyses of potential IBD bio-
markers. Biopsies and serum of biologic drug treatment naïve UC pa-
tients (n= 56) were analysed with quantitative proteomics to de-
termine cytokine and anti-microbial peptide (AMPs) levels [99]. Anti-
TNF responders (n=25) showed different expression patterns of AMP
or proteins associated with AMP response, when compared to non-re-
sponders (n=31). Overall expression of defensin-5α and eosinophil
cationic protein were related to anti-TNF response, whereas high ca-
thepsin, IL-12, IL17A and TNF protein expression were indicators for
non-response. In an additional anti-TNF treatment naïve UC cohort
(n=43) reduced levels of CD14 and CD86 macrophage markers and
chemokine CCL2 in intestinal biopsies were linked to an improved
treatment response 14 weeks after treatment initiaiton [100]. Ad-
ditionally, this study detected lower cell surface expression of CD14 and
CD86 on circulatory monocytes in peripheral blood samples in re-
sponders detectable 2 weeks post-treatment initiation onwards.
Gene expression analysis is useful for understanding potential dis-
ease-associated changes in gene transcription; however, transcriptomic
data cannot always provide information about the functional re-
percussion these changes have, and does not take post-translational
modifications into consideration. Proteomics and other tools of protein
quantification, such as immunohistochemistry and flow cytometry, give
a clearer indication about how functionality may be affected.
Overall, combining data obtained from analysing genomic poly-
morphisms, changes in gene expression, and changes in protein ex-
pression, provides a strong basis for understanding the complex me-
chanisms underlying disease response. Currently, there is insufficient
evidence to support the use of biomarkers in the clinic to predict anti-
TNF response [95]. However, the studies described here are important
steps towards this goal; they describe potential biomarkers which, after
testing in larger cohorts over longer time periods, might prove to be
clinically useful in the future.
6.2. Predicting response to non-anti-TNF biologics
In the step-up therapy model, biologics targeting molecules other
than TNF are administered to those who do not respond to anti-TNFs. It
may be more useful if patients likely to respond to these drugs were
identified before commencing biologics [101,102]. However, non-anti-
TNF biologics have only recently been approved so studies aimed at
identifying biomarkers that predict responses are in their infancy [103].
6.2.1. Microbiota and cellular studies in ustekinumab-treated patients
The microbiota of ˜500 anti-TNFα non-responders with moderate to
severe CD was analysed prior to receiving the IL12/23-targeting drug
ustekinumab [104]. When assessing responses at week 6, it was shown
that ustekinumab responders had significantly higher levels of Faecali-
bacterium and Escherichia/Shigella prior to treatment than non-re-
sponders. Faecalibacterium, an important gut commensal, was suggested
to have the most predictive value because of its ubiquity in the cohort,
and they have previously been proposed as a candidate for probiotic
treatment for CD [105]. However, the microbiome is highly diverse so
despite the broad distribution of Faecalibacterium it alone might not be
sufficient to predict response to ustekinumab [106].
Innate lymphoid cells (ILCs) have recently received much attention
in mucosal immunology. These cells have high cytokine production
capacity and can profoundly influence intestinal immune responses. In
IBD, there is a bias towards ILC1s, which express transcription factors
and cytokines present in Th1 cells. ILC1s are supported by IL-18, and IL-
12, the target of ustekinumab [107,108]. Creyns and colleagues studied
46 CD patients that had failed treatment with anti-TNF and vedoli-
zumab, and were due to receive ustekinumab [109]. Response was
gauged by endoscopic examination 24 weeks after therapy onset. In-
terestingly, ustekinumab responders had significantly lower baseline
levels of peripheral blood ILC1s (p= 0.017) and the authors postulated
that ILC1s cells in the peripheral blood of non-responders migrate into
the gut to overcome ustekinumab-mediated IL-12 blockade. Alter-
natively, the low levels of ILC1s in the blood of ustekinumab responders
might be because more of these cells are in the gut. This could indicate
that IL-12 is active in these patients and explain why they respond to
ustekinumab. This is the first study to examine ILCs during biologic
treatment and, if the findings are validated in a larger independent
cohort, they could pave the way for using ILC1 quantitation as pre-
dictive biomarker of ustekinumab response [109].
6.2.2. Expression studies to predict response to vedolizumab
Boden and colleagues studied peripheral blood from 15 CD and 11
UC or unclassified IBD that were refractory to anti-TNF and due to
receive vedolizumab, the α4β7 blocking antibody. Interestingly, α4β7
expression on CD4+ T cells and Natural Killer (NK) cells prior to
treatment was found to be higher in responders than non-responders
[110]. A separate study of 11 CD and 17 UC patients found that ve-
dolizumab non-responders had higher baseline levels of circulating IL-6
[97], and that CD40 Ligand (100% specificity/sensitivity) and osteo-
calcin (100% specificity, 85% sensitivity) could predict response in CD
or UC patients, respectively. These observations are encouraging, but
the cohort size was small in both of these studies and further validation
is required.
The studies discussed above show that approaches are emerging
that could be used to stratify patients based on their likely respon-
siveness to biologics [95,96,104,105,110]. There are many factors that
will determine the form of IBD a patient has and their response to
biologics, including genetic predisposition, physiological condition,
disease severity, the microbiome and immune function [111]. Gene
expression and cell phenotypes are likely influenced by all these factors
so perhaps these might be the most suitable was of predicting ther-
apeutic responses [112]. To reduce patient discomfort, and maximise
utility, it is desirable to assess these in easily accessible material, such
as peripheral blood. The studies described above provide reasons for
optimism but they need to be validated in larger patient cohorts before
they enter the clinic. We can expect more progress in the near future.
7. Molecular stratification for personalised medicine
The stratification approaches described above could be used to in-
form progression through the step-up and top-down IBD treatment
models. However, the ultimate aim is to move away from these models
and use personalised medicine to direct treatment (Fig. 3). In this sec-
tion, we discuss whether molecular stratification can be used to identify
the unique disease drivers in each patient, and explore the possibility of
more broadly providing personalised medicine for IBD patients.
7.1. Monogenic IBD
The majority of IBD patients have polygenic disease, but in some
paediatric patients with early onset IBD disease is driven by high pe-
netrance alleles or caused by the dysfunction of a single gene
[106,113]. The first genes associated with monogenic IBD were those
encoding IL10 and its receptor (IL-10R). Kotlarz and colleagues iden-
tified ‘loss-of-function’ mutations in either IL10 or IL10R in ˜25% of
patients with severe infantile IBD (refractory colitis and perianal dis-
ease within the first 3 months of life) [114]. Five patients with IL10R
mutations received stem cell therapy to restore IL-10R-mediated sig-
nalling, and this induced clinical remission in all patients for at least 2
years [114].
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Other monogenic causes of disease have also been identified. In
these rare conditions, specific molecular therapies can sometimes be
developed. For instance, a ‘gain-of function’ mutation in the NLR family
CARD domain-containing protein 4 (NLRC4) gene was identified in a 9-
week-old patient who developed early-onset enterocolitis and had
unusually elevated levels of serum IL-18 [115]. NLRC4 activates the
inflammasome, a molecular complex required to induce pro-in-
flammatory cytokines, such as IL-18. Recombinant human IL-18
binding protein was prescribed to inhibit IL-18: it reduced symptoms of
enterocolitis and caused an acute drop in serum inflammatory markers
[113, [115].
Thus, molecular diagnoses and personalised medicine can be used to
successfully treat some IBD patients. However, monogenic IBD accounts
for only a small percentage of IBD [113,116], and applying persona-
lised medicine to polygenic IBD is far more challenging, where genetic
information alone is unlikely to be sufficient [101,113,117].
7.2. Molecular stratification of polygenic IBD
In order to develop personalised treatment in polygenic IBD, studies
are currently attempting to elucidate molecular disease mechanisms of
IBD in more detail. There are, as yet, no examples of successful perso-
nalised therapy in polygenic IBD, i.e. the use of patient information to
develop a tailored therapy. However, given the volume of studies ex-
amining the molecular pathology of IBD and the recent rapid progress
in this field, we are optimistic that such examples will soon begin to
appear.
8. Conclusions
Rapid progress is being made in molecular stratification for IBD,
which is now beginning to allow prediction of disease severity and the
risk of developing complications. Currently the best potential stratifi-
cation strategies utilise serological and faecal markers. Few tran-
scriptomic and metabolomic studies have shown sufficiently promising
stratification results, but with further research they can be expected to
produce more effective ways to stratify in the future.
Development of new forms of stratification will not soon replace the
current methods of diagnosis (e.g., endoscopy), but will likely facilitate
non-invasive disease monitoring and potentially enable more effective
choice of the best treatments. Thus, if a patient is predicted to have
severe disease together with short remission periods, more aggressive
biologics (top-down therapy) and more frequent monitoring would be
recommended to prevent surgery and complications. Patients predicted
to have milder disease could potentially follow the step-up therapy
model.
Biologics targeting TNF, α4β7 or IL-12/IL-23 are effective for many,
but not all patients. Since not every patient responds to these drugs,
molecular stratification is desirable to predict the likelihood of re-
sponse. Candidate biomarkers to predict therapeutic response include
molecules involved in Th1, Th2 and Th17 pathways. The expression of
oncostatin M and mTNFα in the gut, for instance, were reported to be
reliable for differentiating between responders and non-responders
prior to anti-TNF treatment. In addition, studies of stool samples
identified microbial biomarkers to predict the response towards uste-
kinumab (anti-IL-12/IL-23). Furthermore, measurements of the level of
α4β7 integrin expressing cells in peripheral blood can predict responses
to the anti-α4β7 biologic vedolizumab. Unfortunately, none of these
biomarkers are yet proven to be suitable for use in routine clinical
practice.
Despite progress in the field there are still not biomarkers available
that can be used in the clinic for prognosis or to predict treatment re-
sponse, and the clinical need for such biomarkers is high. Ideally, IBD
patients would receive tailor-made treatments upon diagnosis.
Although this may currently be possible for rare cases of monogenic
IBD, more studies elucidating the immune pathways contributing to
polygenic IBD are needed before such personalised medicine can be
generally applicable. Although we are still far away from truly perso-
nalised medicine in IBD, molecular stratification is already beginning to
be used. We are optimistic that by expanding the use of molecular
analyses beyond serological markers, both clinical and cost effective-
ness of IBD therapy can be further enhanced in the future.
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